Patrick Urban

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Norikazu Masuda, Stephen Chia, Mark Clemons, 2017, The Lancet. Oncology.

Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).

Carsten Denkert, Stefan Michiels, Mahdi Rezai, 2017, European journal of cancer.

Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome

Urs Eppenberger, Mauro Delorenzi, Pratyaksha Wirapati, 2007, Breast Cancer Research.